Daily non-political popular news in brief.

Drug combination slows progression of treatment resistant bone marrow cancer

Combining a newly formulated drug with one that is already a standard treatment slows the progression of multiple myeloma, an advanced cancer of the bone marrow cells, according to a clinical trial led by a University of North Carolina at Chapel Hill School of Medicine researcher.

Read more »

Keywords: drug, combination, slows, progression, treatment, resistant, bone, marrow, cancer, slow

« Previous | Next »

Similar news on "Drug combination slows progression of treatment resistant bone marrow cancer":

1. Drug combination effective against multiple myeloma, researchers show
   11-21-2007 · EurekAlert!
   Pairing a new thalidomide derivative with a steroid slows progress of multiple myeloma, an incurable bone marrow cancer, and prolongs the lives of patients who have relapsed from previous treatment, researchers report in the Nov. 22 New England Journal of Medicine.
   Similar news · Read more »
   
2. Penn's Abramson Cancer Center part of major phase III study for myeloma
   11-21-2007 · EurekAlert!
   Researchers from the UPenn's Abramson Cancer Center announced today that findings from two international clinical trials show unprecedented survival for patients with myeloma, a cancer the blood-making cells of bone marrow. Findings show that with the oral drug lenalidomide, in combination with dexamethasone, patients significantly improved by all measures where previous treatments had failed -- including a median survival of nearly three years -- the longest median survival known for this difficult to treat patient group.
   Similar news · Read more »
   
3. Drug combination proves effective against myeloma in Phase I trial
   12-11-2006 · EurekAlert!
   Two "new generation" drugs for the bone marrow cancer multiple myeloma may work even better together than they do individually, according to the results of a multicenter Phase I clinical trial to be presented by Dana-Farber Cancer Institute scientists at the annual meeting of the American Society of Hematology in Orlando, Fla.
   Similar news · Read more »
   
4. Stem cells make bone marrow cancer resistant to treatment
   01-11-2008 · EurekAlert!
   Scientists at the Johns Hopkins Kimmel Cancer Center say they have evidence that cancer stem cells for multiple myeloma share many properties with normal stem cells and have multiple ways of resisting chemotherapy and other treatments.
   Similar news · Read more »
   
5. A faster way to recover from chemotherapy and marrow transplant
   06-20-2007 · EurekAlert!
   Researchers at Children's Hospital Boston report finding a practical way to increase stem cells in blood, suggesting a possible treatment to help patients recover from chemotherapy or bone marrow transplant for cancer, regaining immune function more quickly. The discovery, reported in the June 21 Nature and made possible through high-volume drug screening in fish, marks the first time stem-cell production has been induced by a small-molecule drug.
   Similar news · Read more »
   
6. Phase II study shows HRPC patients with bone metastases see improved survival with ZD4054
   09-25-2007 · EurekAlert!
   New Phase II data presented today suggest that ZD4054, a novel compound in development for the treatment of men with hormone-resistant prostate cancer, could offer a promising improvement in overall survival in men with metastatic HRPC who were asymptomatic or mildly symptomatic for pain.1 Patients who received ZD4054 10mg once-daily experienced a 45 percent reduction in the risk of death compared to placebo.
   Similar news · Read more »
   
7. Survival data presented from phase II study of hormone-resistant prostate cancer patients
   09-25-2007 · EurekAlert!
   The results from a randomized, double-blind, placebo-controlled, Phase II study of ZD4054 -- a specific endothelin A receptor antagonist -- were delivered today at the 14th European Congress of Clinical Oncology (ECCO, 23-27 Sept., Barcelona). The data presented today for ZD4054, an investigational compound in development for the treatment of men with hormone-resistant prostate cancer, showed no differences in progression-free survival but did report encouraging overall survival data.
   Similar news · Read more »
   
8. UCLA researchers discover biomarkers that predict lung cancer patient response to therapy
   01-31-2008 · EurekAlert!
   Researchers at UCLA's Jonsson Cancer Center have discovered biomarkers that predict which patients with advanced non-small cell lung cancer will respond to a combination treatment of the anti-inflammatory drug Celebrex and the growth factor receptor blocker Tarceva.
   Similar news · Read more »
   
9. Gene profiling predicts resistance to breast cancer drug Herceptin
   02-20-2007 · EurekAlert!
   Using gene chips to profile tumors before treatment, researchers at Harvard and Yale Universities found markers that identified breast cancer subtypes resistant to Herceptin, the primary treatment for HER2-positive breast cancer. They say this advance could help further refine therapy for the 25 to 30 percent of breast cancer patients with this class of tumor.
   Similar news · Read more »
   
10. Jefferson scientists find protein potential drug target for treatment-resistant prostate cancer
    12-31-2007 · EurekAlert!
    Scientists at Jefferson's Kimmel Cancer Center in Philadelphia have found that a signaling protein that is key to prostate cancer cell growth is turned on in nearly all recurrent prostate cancers that are resistant to hormone therapy. If the findings hold up, the protein, called Stat5, may be a specific drug target against an extremely difficult-to-treat cancer.
    Similar news · Read more »